CD133: a stem cell biomarker and beyond

Li, Zhong

doi:10.1186/2162-3619-2-17

Cited by 281 publications

(223 citation statements)

References 100 publications

Supporting

Mentioning

204

Contrasting

Unclassified

Order By: Relevance

“…Our study of this human glioma cell line confirms the accumulation or preferential selection of CD133 + cells, a putative brain tumour stem cell marker [15], under prolonged stem cell culture conditions compared to propagation in serum-containing media. Recent studies addressing the effect of different culture conditions in in vitro mouse models of GBM described the robust enhancement of stem cell marker expression and self-renewal capacity of cells transferred from adherent growth to spheroid culture [1].…”

Section: Discussionsupporting

confidence: 52%

The effect of neurosphere culture conditions on the cellular metabolism of glioma cells

Kahlert

Koch

Suwala

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 52%

The effect of neurosphere culture conditions on the cellular metabolism of glioma cells

Kahlert

Koch

Suwala

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The results of this preliminary study was also supported by several other studies that showed a significant increase (p=0.002) of CD133 in lichen planus lesions that turn into squamous cell carcinoma. 28 The existence of a variety of gene expression and chemical mediators/cytokines in premalignant lesions have been studied and proved a meaningful relationship. The discovery of chronic inflammatory cells in all premalignant lesions is assumed to contribute significantly to changes in these lesions into oral cancer.…”

Section: Resultsmentioning

confidence: 99%

Expression of CD133 in various premalignant and proliferative lesions

Amtha

Gunardi

Sandra

et al. 2015

Dent. J. (Majalah Kedokteran Gigi)

View full text Add to dashboard Cite

“…The expression of CD133 is dynamic and responds to changes in the cell microenvironment. CD133 is involved in diverse cellular processes, including the uptake of glucose and transferrin, autophagy, membrane-membrane interaction, and matrix metalloproteinase functions (21). The expression of CD133 on the cell surface was shown to be a specific marker for CSCs in a number of malignancies, including lung cancer (6,22).…”

Section: Discussionmentioning

confidence: 99%

The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma

Miyata

Oyama

Yoshimatsu

et al. 2017

View full text Add to dashboard Cite

Abstract. Background/Aim: Aldehyde dehydrogenase-1A1 (ALDH1A1) and CD133 have been identified as markers of cancer stem cells (CSCsDespite continuous efforts to improve therapeutic response, lung cancer is the most common cause of cancer-related deaths in Japan, with adenocarcinoma by far the most common histology, accounting for nearly 70% of lung cancer cases (1). Cancer stem cells (CSCs) have the ability for selfrenewal and multipotently differentiate (2). CSCs may be highly resistant to chemotherapy and radiation, and be responsible for tumor initiation, progression and metastasis (3, 4). Accumulating evidence supports the existence of a CSC phenotype in human lung cancer (3, 5-7). The metabolic marker aldehyde dehydrogenase isoform 1A1 (ALDH1A1) and the cell-surface marker CD133 are reported to be markers of lung CSCs (3). We, therefore, investigated ALDH1A1 and CD133 expression in a retrospective cohort of 92 patients with lung adenocarcinoma. The objectives were to determine the association between ALDH1A1 and CD133 expression in lung adenocarcinoma, the relationship between their expression and the clinichopathological parameters, and the prognostic value of ALDH1A1 and CD133. Materials and MethodsPatient population and clinicopathological data. We examined a series of 154 Japanese patients with lung adenocarcinoma who underwent surgical treatment at Fukuoka-Wajiro Hospital, Fukuoka, Japan from 2006-2012. Ninety-two out of 154 (59.7%) patients were selected based on the following inclusion criteria: (i) no chemotherapy or radiotherapy before surgery, and (ii) the availability of an adequate paraffin block and clinicopathological data for the analysis. Follow-up information was obtained from the patients' records. Routinely collected clinicopathological data included age, gender, smoking history and pathological stage. There were 49 males (53%) and 43 females (47%), with a median age of 71 years (range=40-92 years) at the time of surgery; 43 (47%) patients were <70 years and 49 (53%) were ≥70 years of age. Half of the patients (n=46) had a smoking history. The pathological stages were: stage I, n=62 (67.4%); stage II, n=14 (15.2%); stage III, n=12 (13.0%); and stage IV, n=4 (4.4%) (TNM staging of lung cancer) (8). The median follow-up period was 1,702 days (range=4-3679 days). Recurrence was diagnosed by computed tomography alone or combined with positron-emission tomography.

show abstract

CD133: a stem cell biomarker and beyond

Cited by 281 publications

References 100 publications

The effect of neurosphere culture conditions on the cellular metabolism of glioma cells

The effect of neurosphere culture conditions on the cellular metabolism of glioma cells

Expression of CD133 in various premalignant and proliferative lesions

The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma

Contact Info

Product

Resources

About